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Abstract
Complex diseases involve dynamic perturbations of pathophysiological processes during disease progression.
Transcriptional programs underlying such perturbations are unknown in many diseases. Here, we present core
transcriptional regulatory circuits underlying early and late perturbations in prion disease. We first identified cellular
processes perturbed early and late using time-course gene expression data from three prion-infected mouse strains.
We then built a transcriptional regulatory network (TRN) describing regulation of early and late processes. We found
over-represented feed-forward loops (FFLs) comprising transcription factor (TF) pairs and target genes in the TRN.
Using gene expression data of brain cell types, we further selected active FFLs where TF pairs and target genes
were expressed in the same cell type and showed correlated temporal expression changes in the brain. We finally
determined core transcriptional regulatory circuits by combining these active FFLs. These circuits provide insights
into transcriptional programs for early and late pathophysiological processes in prion disease.
Keywords: Murine PrP-prion disease, Gene expression, Transcriptional regulatory circuits, Feed-forward loops, Brain
cell type
Introduction
Living organisms execute diverse cellular processes by
operation of biological networks [1]. Such operation of
the networks is perturbed under pathological conditions,
involving changes of nodes in their abundances and/or
edges in their activities. These changes result in dynamic
perturbations of pathophysiological processes during the
course of disease progression [2]. Biological networks in-
clude protein-protein interaction (PPI) [2], transcrip-
tional regulatory networks (TRNs) [3], and metabolic
networks [4]. TRNs delineate the regulations of target
genes associated with cellular processes by transcrip-
tional factors (TFs). TRNs are composed of regulatory
motifs, such as transcriptional feedback and feed-
forward loops [5, 6]. Expression changes of TFs and
target genes included in the regulatory motifs along dis-
ease progression can represent perturbations of early-
and late-stage disease processes. However, the regulatory
motifs underlying these disease-perturbed processes
have rarely been studied longitudinally through both
early and late stages.
Transmissible PrP-prion disease, which is caused by
misfolding, aggregation, and spread of misfolded forms
of prion protein (PrPSc), is an excellent model system to
study dynamic perturbations of pathophysiological pro-
cesses during disease progression since disease initiation
is defined by inoculation. Prions are proteins that self-
replicate through templated misfolding, accumulation,
and aggregation, often, but not always, accompanied by
formation of amyloid [7]. Some prions cause neurode-
generative diseases [8–11]. The prototypical prion dis-
eases, which include scrapie in sheep and Creutzfeldt-
Jakob Disease (CJD) in humans, are caused by misfold-
ing of normal isoforms of prion protein (PrPC) to malig-
nant disease-causing isoforms (PrPSc). As a group,
neurodegenerative diseases involving PrP are designated
as PrP-prion diseases that can be transmitted experi-
mentally as are the mouse prions used in this study, or
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iatrogenically, as exemplified by transmission of disease
by contaminating CJD-PrPSc in surgical procedures,
transplantation, or injection of cadaver-derived human
pituitary growth hormone [12, 13].
Additional neurodegenerative diseases share the pro-
cesses that are the defining features of prion disorders–
self-replication of specific proteins through templated
changes in conformation, aggregation, spread from cell-to-
cell within the brain, and the ability of protein aggregates to
specifically infect cultured cells and transgenic mice [8, 9].
The α-synucleinopathy multiple system atrophy (MSA) has
been transmitted to mice expressing human α-synuclein
transgenes by inoculation of brain homogenates from de-
ceased patients [14]. MSA prions also infected cultured re-
porter cells [15]. Similarly, tau prions from Alzheimer’s
disease (AD) and chronic traumatic encephalopathy propa-
gated in cultured cells [16], and pathological tau from AD
or corticobasal degeneration brains induced spreading
tauopathy in tau transgenic mice [17]. Aβ prions also prop-
agated in mice and cultured cells, maintaining conforma-
tionally determined strain properties [18]. Strikingly, the
possibility of human-to-human transmission of AD path-
ology is supported by the presence of Aβ pathology at an
early age in some patients that received cadaveric pituitary
growth hormone [19].
Inoculation of prions defines the start of the disease
process. Following inoculation, when prion replication is
initiated in the host, there is a long interval when prions
accumulate with no obvious clinical signs. The clinical
phase is relatively short, though pathological changes are
occurring. The pathological features over the interval be-
tween inoculation, illness, and death comprise prion rep-
lication and accumulation [20], microglia and astrocyte
activation [21, 22], synaptic degeneration [23], and neur-
onal cell death [24]. Through comprehensive time-
course gene expression analyses of eight mouse strains
infected with one of two distinct prion strains (RML and
301 V), we previously showed dynamic perturbations of
cellular processes associated with these four pathological
features along disease progression at the whole brain
level [2]. In the early stage, the complement system and
leukocyte infiltration associated with microglia and
astrocyte activation are the first response to PrPSc mis-
folding and aggregation. In the middle stages of PrPSc
accumulation, glycosaminoglycans, cholesterol, and
sphingolipid metabolisms become activated. Finally, in
the late stage of disease, synaptic transmission and axon
guidance expressions of genes associated with synaptic
degeneration are down-regulated, followed by activation
of cellular processes associated with neuronal cell death.
Several network models have been developed based on
our time-course gene expression profiles of eight prion-
mouse strain combinations. First, we provided dynamic
PPI network models describing temporal perturbations
of cellular processes associated with the aforementioned
four groups of pathological features. Second, for each
prion-mouse strain combination, Newaz et al. developed
protein function network (PFN) models describing func-
tional associations among differentially expressed genes
(DEGs) at individual time points and then proposed PI3K-
AKT signaling pathway as a core regulatory module
through the analysis of the PFNs [25]. Third, Crespo et al.
provided a gene regulatory network model and then iden-
tified a core module for regulation of prion replication
and accumulation and neuronal cell death [26]. Despite
the gene regulatory network, a TRN describing the regula-
tion of early and late pathological features by TFs is lack-
ing. Here, we present core transcriptional regulatory
circuits that represent early and late perturbations of cel-
lular processes along prion disease progression, providing
insights into transcriptional programs for early and late
pathophysiological processes in prion-infected brains. The
significance of our findings may extend beyond PrP-prion
disease to other, more common neurodegenerative dis-
eases that share prion-related mechanisms, though the re-
sults presented here were all obtained from PrP-prion
diseases, which in this paper are subsequently referred to
as ‘prion diseases’.
Materials and methods
Identification of major differential expression patterns
To identify the genes showing shared dynamic expres-
sion patterns in RML infected B6, FVB, and Prnp0/wt,
we first computed log2-fold-changes between prion-
infected and control samples in each of the three
mouse-prion strain combinations (B6-RML, FVB-RML,
and Prnp0/wt-RML). After combining the three sets of
log2-fold-changes into a fold change matrix, we then ap-
plied the orthogonal non-negative matrix factorization
(ONMF)-based clustering method [27] to the fold
change matrix. To prevent the NMF result from being
biased toward the combination with large fold-changes,
each of the matrices in each mouse-prion combination
was converted into a vector and then the vectors from
the three mouse-prion combinations were normalized by
the quantile normalization method [28]. Finally, the nor-
malized vectors were reconstructed into log2-fold change
matrixes for the three mouse-prion combinations. NMF
was then performed using the reconstructed log2-fold
change matrixes with the following parameters: C = 1,
T = 0.5, K = 5, the number of bases = 20, the number of
iterations in each NMF application = 1000 and the num-
ber of NMF applications = 30. The resulting 30 differen-
tial expression patterns were categorized into the
following three groups (Additional file 1: Figure S1): 1)
three patterns shared across all the three combinations
(Clusters 1, 2, and 3); 2) five patterns shared between
two of the three combinations (Clusters 4, 6, 7, 8, and
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20); and 3) the remaining 12 patterns observed only in
one of the three combinations. To focus on the patterns
shared across the three combinations, we selected Clus-
ters 1, 2, and 3 representing late (LU) and early up-
regulation (EU) and down-regulation (DN), respectively,
and then identified the genes whose expression is signifi-
cantly (P < 0.01) correlated with the selected patterns
[27]. To remove potential false positives, we further se-
lected the genes whose maximum absolute log2-fold-
changes are larger than a cutoff value at least in one of
the three combinations. The cutoff value was deter-
mined as the 95th percentile of the log2-fold-changes.
Using this method, 107 (Cluster 1), 502 (Cluster 2), and
274 genes (Cluster 3) were finally identified as EU (Fig.
1a), LU (Fig. 1b), and DN (Fig. 1c) genes, respectively.
Identification of cellular functions represented by EU, LU,
and DN genes
We performed enrichment analyses of GOBPs for 107
EU, 502 LU, and 274 DN genes using The Database for
Annotation, Visualization and Integrated Discovery (DA-
VID, ver 6.7) software [29]. Among the resulting GOBPs,
we selected the GOBPs with P < 0.05 and count > = 3 as
those enriched by EU, LU, and DN genes (Tables S2).
When selecting GO terms related to the three prion dis-
ease pathophysiological features (Figs. 1d-e), for multiple
redundant GO terms representing a cellular event, we
selected only the most representative ones assigned to
the largest numbers of genes in each pattern.
Analysis of TF-target gene data
We obtained 7489 TF-target interactions for 748 of the 883
genes from MetaCore™ (ver 6.7 [30]; and Ingenuity Pathway
Analysis (IPA) (Additional file 2: Table S3). We used ‘Direct
interactions’ and ‘Transcription regulation’ options in
MetaCore and ‘Upstream Regulator’ of ‘Core analysis’ in
IPA. For each TF, we obtained the number of targets using
the TF-target interactions and then computed statistical
significance for the target number based on the following
random sampling experiments: 1) 883 genes were randomly
Fig. 1 Early and late alterations of cellular processes associated with prion diseases along disease progression. A-C) Three major differential
expression patterns shared in B6-RML, FVB-RML, and Prnp0/+ − RML along disease progression. These patterns included 107 early up-regulated
(EU; A), 502 late up-regulated (LU; B), and 274 down-regulated genes (DN; C). Gene expression changes were shown as log2-fold-changes
between prion-infected and control brains at individual time points. Red and green colors indicate up- and down-regulation (positive and
negative log2-fold-changes; see the color bar), respectively. D) Gene ontology biological processes (GOBPs) enriched by the genes in each
expression pattern. The color bar indicates the gradient of the enrichment p-value obtained from the DAVID software. Different colors were used
to distinguish the enrichment for EU (orange), LU (magenta), and DN patterns (green). GOBPs were categorized into four (Groups 1 to 4) based
on the enrichment patterns in the EU, LU, and DN gene clusters
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selected from the genome; 2) the number of targets for the
TF was obtained; 3) Steps 1–2 were repeated 10,000 times;
4) an empirical distribution was estimated using Gaussian
kernel density estimator (Bowman. 1997); and 5) an FDR
for the observed target number was calculated using the
empirical distribution as previously described [31]. Finally,
we selected 114 major TFs with FDR < 0.1.
Reconstruction of the TRN
We generated a TRN for the TFs and their targets using
7489 TF-target interactions obtained as described in the
previous section. In the TRN, we arranged the nodes such
that the nodes with the same GOBP were grouped into the
GOBP module. We then decomposed the TRN into three
subnetworks (PrP accumulation, microglial/astrocytic acti-
vation, and synaptic degeneration), based on the associa-
tions of the GOBP with the three pathophysiological
features (Fig. 2b and Additional file 1: Figure S2B). The
nodes with no TF-target interaction available were located
to the modules with the same GOBPs while the nodes with
no assigned GOBP available were located to the modules
functionally closest to them, based on their functional in-
formation obtained from prior literature.
Identification of over-represented regulatory motifs
To assess characteristics of scale-free and hierarchical
networks of two TRNs for all 467 TFs and 114 major
TFs, respectively, for each node, we computed in- and
out-degrees (k) and clustering coefficient C as previously
described [32]. We then performed log-log scatter plot
analyses of in- or out-degree vs. the degree distribution
P(k) and degree vs. the clustering coefficient distribution
C(k) (Additional file 1: Figures S3A-B). The analyses re-
vealed negative linear relationships on the log-log scatter
plots, suggesting that the TRN is scale-free and hierarch-
ical. Next, to identify the over-represented regulatory
structures between the TFs and their target genes, we
performed enrichment analyses on 13 previously re-
ported motifs using mfinder software [33]. Briefly, for
Motif i, we generated 1000 randomized TRNs from the
real TRN by randomly rewiring the edges in the TRN.




where Nreali is the frequency of Motif i in the real TRN,
and mean(Nrandi ) and std.(N
rand
i ) represent the mean and
standard deviation of the frequencies observed in the
1000 randomized TRNs. Finally, the Z-score was then
normalized to estimate its relative significance by the
norm of the Z-score vector (Milo et al., 2004): ~Zi ¼ ZiðPZ2i Þ1=2
.
Association of targets for TF pairs with DEGs involved in
prion disease-related processes
For the overlapping m targets for a TF pair with n genes
involved in a cellular process associated with prion
disease, we estimated the significance of the overlapping












Regulation of GOBPs by 18 key TFs
To identify the relationships between 18 key TFs and 40
GOBPs enriched by the 883 EU, LU, or DN genes, the
number of target genes regulated by each of the 18 key
TFs among the EU, LU, or DN genes involved in each
GOBP was counted. When the number of target genes is
less than 2, the percentages were set to zero to remove
false interpretation arising from high percentages due to
the residual number of target genes.
Results
Dynamic perturbations of cellular processes associated
with prion diseases
Previously, we proposed core genes associated with patho-
genesis of prion disease that showed shared dynamic
changes in differential expression along progression of
prion disease [2]. To identify these core genes, we first se-
lected the following three combinations among the eight
prion strain-mouse strain combinations previously re-
ported [2]: 1) inbred C57BL/6 J (B6) and 2) FVB/NCr
(FVB) mouse strains infected with RML (B6-RML and
FVB-RML), and 3) FVB background mice expressing half
of the amount of PrPC (Prnp0/wt) as wild type mice in-
fected with RML (Prnp0/wt-RML). Prnp0/wt-RML mice
have a longer incubation times (more than 250 days) than
B6- and FVB-RML (~ 150 days) and a slower rate of syn-
aptic degeneration than B6- and FVB-RML, despite a rate
of PrPSc accumulation similar to that of FVB-RML. The
inclusion of Prnp0/wt-RML enabled us to reliably discern
early and late responsive genes.
Using the time-course gene expression profiles of the
three selected prion-mouse strain combinations (B6-
RML, FVB-RML, and Prnp0/wt-RML), we performed
the orthogonal non-negative matrix factorization
(ONMF) clustering [34] with the number of clusters =
20. Among the 20 clusters (Additional file 1: Figure S1),
we focused on three clusters (Clusters 1–3) including
883 differentially expressed genes (DEGs) that showed
the following shared differential expression patterns
across the three combinations: 107 early up-regulated
genes in Cluster 1 (Fig. 1a, EU); 502 late up-regulated
genes in Cluster 2 (Fig. 1b, LU); and 274 down-regulated
genes at the late stage in Cluster 3 (Fig. 1c, DN). Many of
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these 833 DEGs have been identified previously as DEGs
in prion-infected mice (Additional file 2: Table S1) [35–
42]. Moreover, of the 883 DEGs, 270 and 541 overlapped
with the previous 333 core genes and 923 prion disease-
related genes identified from five prion-mouse strain
combinations (B6-RML, FVB-RML, C57BL/6.I-1(B6.I)-
RML, B6-301V, and B6.I-301 V), respectively (Additional
file 2: Table S1).
To examine how these genes represent early and late
perturbations of cellular processes associated with prion
Fig. 2 TRN describing transcriptional regulation of cellular processes associated with prion diseases. A-C) Early (EU; A) and late up-regulated (LU; B)
and down-regulated genes (DN; C) regulated by the TFs. In the stacked bars, the dark and light shaded areas of the target genes represent the
portions of the EU, LU, and DN genes regulated by the differentially expressed TFs (DETFs) and non-DETFs, respectively, whereas the mid-color shaded
areas represent the portions of the genes regulated by both DETFs and non-DETFs (see the arrows). Different colors were used to distinguish the TF-
target regulatory relationships for EU (orange), LU (magenta), and DN patterns (green). The numbers regulated by the TFs are denoted. D) Percentages
of the target genes regulated by the 18 key TFs in each group of 107 EU, 502 LU, and 274 DN genes. The color bar represents the gradient of Z-score
reflecting the percentage of the target genes regulated by each TF (Materials and Methods). E) A TRN describing regulations of 18 key TFs with their
targets. The TRN is categorized into three transcriptional regulatory subnetworks associated with PrPSc accumulation, microglial/astrocytic activation,
and synaptic degeneration, respectively. The 18 key TFs are arranged in a circle surrounding the three subnetworks. Node shapes denote TFs
(diamonds) and target genes (circles); node colors represent EU (orange), LU (purple), and DN (green) nodes; and edge types indicate activation
(arrow), inhibition, and unspecified interactions (blunted arrow). F) Percentages of the target genes regulated by the 18 key TFs in the three
subnetworks. The color bar represents the gradient of the percentage of the target genes regulated by each TF
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diseases, we performed enrichment analyses of gene
ontology biological processes (GOBPs) for EU, LU, and
DN genes (Fig. 1d; Additional file 2: Table S2) using
DAVID software [29]. The GOBPs represented by each
cluster of genes reflect cellular processes perturbed with
the corresponding dynamics. Early activated GOBPs
(Groups 1 and 2 in Fig. 1d) include the processes related
to innate immune or inflammatory responses (e.g. anti-
gen processing and presentation, complement activation,
pattern recognition receptor signaling pathway, phago-
cytosis, and leukocyte activation). Late activated GOBPs
(Group 3 in Fig. 1d) include: 1) innate and/or adaptive
immune responses (e.g. cytokine production, cytokine-
mediated signaling, NFKB/MAPK signaling, and B-cell
activation); 2) PrPSc deposition and transport (vacuole
organization, regulation of proteolysis, extracellular
matrix organization, and actin cytoskeleton
organization); 3) lipid metabolism and transport
(sphingolipid metabolism and cholesterol transport); and
4) stress responses (angiogenesis, responses to reactive
oxygen species, and apoptosis). Finally, down-regulated
GOBPs (Group 4 in Fig. 1d) include synaptic
degeneration-related processes (axon guidance, calcium
ion transport, synaptic transmission, and gamma-
aminobutyric acid signaling). Early and late perturba-
tions of these processes were consistent with those in
the previous PPI network models [2].
TRN describing transcriptional regulation of early and late
perturbed processes associated with prion diseases
To investigate transcriptional regulation underlying early
and late perturbations of cellular processes associated
with prion diseases, we built TRN describing regulations
for EU, LU, and DN genes by 467 TFs (Additional file 1:
Figure S2A) based on TF-target interactions in Meta-
Core™ (ver 6.7) and Ingenuity Pathway Analysis (IPA).
Based on these TF-target interactions, the upstream TFs
were available for 84.7% (748 of 883) of the EU, LU, DN
genes. The 467 TFs in the TRN were first categorized
into two groups based on their differential expression: 1)
40 differentially expressed TFs (DETFs) including 5 EU,
24 LU, and 11 DN TFs and 2) 427 non-differentially
expressed TFs (non-DETFs). Of the 107 EU genes, 90
(84.1%) can be transcriptionally regulated by 26 DETFs
and 160 non-DETFs (Fig. 2a). Of the 502 LU genes, 448
(89.2%) can be regulated by 36 DEFTs and by 368 non-
DETFs (Fig. 2b). Finally, of the 274 DN genes, 210
(76.6%) can be regulated by 24 DETFs and 177 non-
DETFs (Fig. 2c). Interestingly, the DETFs can regulate
larger numbers of the target genes per TF compared to
the non-DETFs (Figs. 2a-c). For example, 66 EU genes
were regulated by 26 DETFs (66/26 = 2.54), while 85 EU
genes were regulated by 160 non-DETFs (85/160 = 0.53)
(Fig. 2a). These data indicate greater relative importance
of the DETFs in transcriptional regulation of the EU,
LU, and DN genes.
Among the 467 TFs, we next selected 114 major TFs
that have significant (FDR < 0.1) numbers of target genes
in EU, LU, or DN clusters (Additional file 2: Table S3).
Based on the observation that DETFs have larger num-
bers of targets than non-DETFs, among the 114 major
TFs, we selected the following 18 DETFs as key TFs that
play important roles in transcriptional regulation of cel-
lular processes represented by the EU, LU, and DN
genes: 1) 4 EU-DETFs (Cebpa/d, Irf8, and Nupr1); 2) 12
LU-DETFs (Atf3, Cebpb, Jun, Nfe2l2, Rela, Spi1, Srebf1,
Stat3/6, Ikzf1, Nfkbia, and Id3); and 3) 2 DN-DETFs
(Atf2 and Sox2). Interestingly, these 18 key TFs, includ-
ing two down-regulated TFs, were found to regulate
mostly the EU and LU genes, according to the TF-target
interactome data used (Fig. 2d). Several of the 18 key
TFs have been reported to have potential involvement in
prion diseases or other neurodegenerative diseases (Add-
itional file 2: Table S3). For example, Stat3 showed in-
creased phosphorylation in mouse brains infected with
prions, suggesting its potential roles in pathogenesis of
prion disease [43]. Also, Atf2, an abundant TF in normal
brains, was significantly down-regulated in the brains
with Alzheimer’s, Parkinson’s, and Huntington’s dis-
eases, consistent with our findings [44]. Moreover, a
dominant negative TF Jun significantly reduced neuronal
death in prion infected neurons [45], and Nfe2l2, also
known as Nrf2, was strongly up-regulated in multiple
sclerosis lesions and found to be associated with active
demyelination in the lesions [46].
We then developed a TRN model using the 18 key
TFs and 315 target genes (42.1% of 748 DEGs) based on
the TF-target interactome data (Fig. 2e). The target
genes in the TRN were organized into three subnet-
works that represent three aspects of disease: PrPSc ac-
cumulation, microglial/astrocytic activation, and
synaptic degeneration [2]. We then examined how sig-
nificantly the 18 key TFs regulate cellular processes as-
sociated with the three pathological features (Fig. 1d) by
computing the fraction of their target genes to the DEGs
involved in each cellular process (Additional file 1: Fig-
ure S2B; Additional file 2: Table S4). For example, the
processes represented only by the EU genes (Group 1 in
Additional file 1: Figure S2B) are regulated by 10 of the
18 TFs (Cebpa/d and Irf8 EU TFs; and Cebpb, Jun, Rela,
Spi1, Stat3, Nfkbia, and Atf2 LU TFs). The processes
represented by EU and/or LU genes (Groups 2 and 3 in
Additional file 1: Figure S2B) are regulated by most of
the 18 TFs. The processes represented by the DN genes
(Group 4 in Additional file 1: Figure S2B) are regulated
mainly by eight of the 18 TFs (Jun, Rela, Atf2, Cebpb,
Stat3, Spi1, and Srebf1 LU TFs; and Sox2 DN TF).
Taken together, the TRN delineated by the 18 key TFs
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and the 315 target genes effectively covered transcrip-
tional regulation of early and late cellular processes asso-
ciated with the pathological features of prion diseases
(Fig. 2f).
Over-represented regulatory motifs in the prion disease-
associated TRN
Several methods have been developed for analyzing regu-
latory structures of biological networks to identify core
regulatory motifs or modules in the networks, including
significant area search, network propagation, clustering-
based methods, and network motif analysis [6]. To deter-
mine a method suitable for our TRN, we first examined
the topological characteristics of the original TRN con-
structed for all 467 TFs by analyzing distributions of de-
grees and clustering coefficients for nodes. The
distributions showed that the TRN has the features of
both scale-free and hierarchical networks (Figs. S3A-B),
indicating that the TRN may include functional regulatory
motifs [33]. Collective operations of network motifs com-
posed of TFs and their targets characterize early and late
induction or repression of target genes. Thus, among the
previous methods, we employed the analysis of network
motifs (Fig. 3a, top left) to examine detailed transcriptional
regulatory structures in our TRN associated with early
and late alterations of target genes.
For network motif analysis, we performed the enrichment
analysis of 13 different previously reported regulatory mo-
tifs, each of which included a pair of TFs and a target gene
(TFi-TFj in Fig. 3a, upper left), as previously described [47].
In this analysis, we used two TRNs constructed for all 467
TFs in addition to the 114 major TFs, not for the TRN for
the 18 key DETFs to avoid bias toward the key DETFs in
the enrichment analysis. The analysis revealed that among
the 13 regulatory motifs, only two motifs (Motifs 7 and 10)
including feed-forward loops were significantly (P < 0.01)
over-represented consistently in the two TRNs (Fig. 3a).
Thus, we used the TRN for the 114 major TFs for the fol-
lowing analysis to focus on Motifs 7 and 10 defined by the
major TFs. The TRN included 6329 Motif 7 and 533 Motif
10 that comprised 95 and 15 major TFs, respectively, and
large portions of the DEGs as target genes (56 EU, 228 LU,
and 54 DN genes for Motif 7; and 30 EU, 125 LU, and 23
DN genes for Motif 10) (Fig. 4b; Additional file 2: Table
S5). Interestingly, Motifs 7 and 10 were also found to be
over-represented in the TRNs for E. coli, yeast, fly, and/or
sea urchin [47], suggesting that the TRN in prion disease
includes key regulatory structures conserved in mammalian
TRNs in spite of the incomplete nature of TF-target data.
We showed above that the DETFs have higher contri-
butions to regulation of target genes than non-DETFs
(Figs. 2a-c). Thus, among the TF pairs in Motifs 7 and
10, we next selected 48 and 20 DETF pairs from 6329
Motif 7 and 533 Motif 10, respectively (Fig. 3c and Add-
itional file 1: Figure S3C, 2nd box). Finally, among them,
we identified 20 and 15 key DETF pairs that were signifi-
cantly (FDR < 0.1) enriched in the 6329 Motif 7 and 533
Motif 10, respectively (Fig. 3c and Additional file 1: Fig-
ure S3C, 4th box). Interestingly, these selected key DETF
pairs (Fig. 3d) included the 18 key DETFs (Fig. 2d), tar-
geting different sets of 178 genes in Motifs 7 and 10, re-
spectively. To understand the contribution of the key
Fig. 3 Over-represented regulatory motifs in the TRN. A) Two over-represented transcriptional regulatory motifs among the 13 previously
reported regulatory motifs. A regulatory structure among two TFs and their targets in each motif is shown (top left). A large positive Z-score
indicates significant over-representation of the corresponding motif. Two (Motifs 7 and 10) significantly (P < 0.01) over-represented motifs were
denoted by the arrows. B) Regulatory information of the two over-represented motifs, Motifs 7 and 10. The over-representation p-value, the
number of the motifs in the TRN, the numbers of TFs and TF pairs in the motifs, and the numbers of EU, LU, and DN targets in the motifs are
shown. C) A schematic for identification of key DETF pairs significantly enriched in Motif 7. See text for details. D) Heat map showing prion
disease-associated processes significantly targeted by the key DETF pairs. Statistical significance (P-value) was computed with the hypergeometric
test and then transformed into Z-score (Materials and Methods), which was displayed in the heat map
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DETF pairs to the regulation of cellular processes related
to prion disease, we then examined how significantly
their target genes in Motifs 7 and 10 overlapped with
the DEGs involved in cellular processes (Fig. 1d) associ-
ated with the pathological features in prion diseases. A
majority of the key DETF pairs showed significant (P <
0.01) overlaps of their targets with the DEGs involved in
cellular processes related to PrPSc replication and accu-
mulation and microglia and astrocyte activation, suggest-
ing their strong associations with these pathological
features (Fig. 3d and Additional file 1: Figure S3D).
Regulatory motifs that can be operative in individual cells
of the brain
In diverse types of cells, such as astrocytes, microglia, ol-
igodendrocytes, and neurons in the brain, molecular net-
works may undergo alterations during the progression of
prion disease [7]. Our gene expression data were gen-
erated from the whole brain, providing mRNA expres-
sion levels from the mixture of diverse cells in the
brain. Thus, it is difficult to sort out in what cell
types Motifs 7 and 10 were altered by prion infection.
To examine whether Motifs 7 and 10 can be opera-
tive in individual cell types, we first analyzed whether
both TFs in each selected TF pair were expressed in
the same cell type using previously reported gene ex-
pression data of seven cell types in the mouse brain,
including microglia, astrocytes, neurons, oligodendro-
cyte precursor cells (OPCs), newly formed oligoden-
drocytes (NFOs), myelinating oligodendrocytes
(MYOs), and endothelial cells [48]. For example, for
Cebpa-Jun pair forming Motif 7, both Cebpa and Jun
were found to be expressed only in microglia, neu-
rons, and OPCs among the seven cell types (Fig. 4a).
Fig. 4 Regulatory motifs potentially operative in individual cells of the brain. A) Expression levels (FPKMs) of Cebpa and Jun in astrocytes (Astro),
neurons (Neuro), oligodendrocyte precursor cells (OPCs), newly formed oligodendrocytes (NFOs), myelinating oligodendrocytes (MYOs), microglia
(Micro), and endothelial cells (Endot). Colors indicate Cebpa (sky blue) and Jun (dark blue), respectively. B) Radar plots showing expression levels
(FPKMs) of target genes regulated by Cebpa-Jun pair in the indicated cells. Different colors were used to distinguish the cell types. C) Log2-fold-
changes of target genes regulated by the Cebpa-Jun pair in the B6-RML combination. Colors indicate Cebpa (sky blue), Jun (dark blue), and
targets (gray). D) Pearson correlation coefficients between log2-fold-changes of Cebpa and Jun (left bar) and distributions of Pearson correlation
coefficients of log2-fold-changes of their target genes with those of Cebpa (sky blue boxplot) or Jun (dark blue boxplot). F) Core TF pairs that
could be operative in each cell type, which were highlighted in yellow
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To evaluate whether TFs were expressed, FPKM ≥5
was used as a cutoff as in Zhang et al [48]
We then examined whether such expressed TF pairs
had significant regulatory power by analyzing the num-
bers of their target genes expressed in the same cell
types. The Cebpa-Jun pair had 51 targets in the 6329
Motif 7, and significant (FDR < 0.1) numbers of the tar-
get genes were found in all three cell types (14, 28, and
37 genes in neuron, OPCs, and microglia, respectively)
(Fig. 4b), suggesting that Motif 7 formed by Cebpa-Jun
pair and their targets can be operative with significant
regulatory power in these three cell types. Finally, we an-
alyzed the correlation between differential expression
patterns of TFs and their targets, which were expressed
in the same cell type, in the whole brain data for the B6-
RML combination along disease progression (Fig. 4c).
For the Cebpa-Jun pair, Cebpa and Jun first showed a
significant (P < 0.01) positive correlation (0.84) between
their differential expression patterns along the progres-
sion of prion disease (Fig. 4d). Additionally, the targets
expressed in OPCs and microglia, yet not in neurons,
showed significant positive correlations (≥ 0.6 statisti-
cally) with Cebpa and Jun (Fig. 4d). All these data sug-
gest that Motif 7 formed by Cebpa-Jun and its targets
can act as a functional motif with significant regulatory
power in OPCs and microglia during the progression of
prion disease.
We applied the same procedure to all 20 and 15 key
DETF pairs selected for Motifs 7 and 10, respectively,
and identified 8 and 6 key DETF pairs for Motifs 7 and
10, respectively, which could be operative with signifi-
cant regulatory power in one of the seven cell types (Fig.
4e and Additional file 1: Figure S4). Interestingly, these
DETF pairs were found to have significant regulatory
power most strongly in microglia (9 and 3 pairs for Mo-
tifs 7 and 10, respectively) and OPCs (7 and 2 pairs for
Motifs 7 and 10, respectively). Only few DETF pairs had
significant regulatory power in astrocytes (3 pairs), neu-
rons (1 pair), MYO (0 pair), and endothelial cells (3
pairs). Moreover, the comparison of the DETF pairs be-
tween microglia and OPCs revealed that the target gene
counts for the DETF pairs were higher in microglia than
in OPCs (Fig. 4b). Collectively, all these data suggest that
these key regulatory motifs are employed in microglia
and OPCs to regulate the target genes in the two cell
types. Moreover, they are more strongly operative in
microglia than in OPCs.
Core transcriptional regulatory circuits for dynamic
activation of cellular processes
To understand collective actions of the regulatory motifs,
we next combined all the regulatory Motifs 7 and 10 that
could be operative in microglia and OPCs with strong
regulatory power and identified core transcriptional
regulatory circuits (TRCs) including key DETF pairs and
their target genes in the selected Motifs 7 and 10 in the
two cell types (Figs. 5a-b). In the microglial and OPC
TRCs, EU and LU genes were targeted by EU or LU
DETFs and found to be more regulated by both EU and
LU DETFs than by either EU or LU DETFs alone (Figs.
5c-d). Interestingly, for the LU target genes, their fold-
changes tended to be higher when regulated by both EU
and LU DETFs than by either EU or LU DETFs alone
(Figs. 5e-f). All these data suggest that EU DETFs modu-
late the expression of LU target genes, and LU DETFs also
modulate the expression of EU target genes at the late
stage of prion diseases.
Comparisons of the nodes in the microglial and OPC
TRCs showed that 8 DETFs and 18 target genes were
shared between the two TRCs, which corresponded to
80% of the DETFs and 43% of the target genes in the
microglial TRC, suggesting that the same DETFs target
different sets of genes between microglia and OPCs
(Figs. 5a-b). The target genes in the microglial TRC were
mainly involved in early inflammatory and immune re-
sponses (Fig. 1d) represented by the EU genes (Fig. 5g;
Additional file 2: Table S6). Compared to the microglial
TRC, the OPC TRC included the target genes that were
mainly involved in the relatively later immune responses
and responses to oxidative stress and steroid hormones
represented by the LU genes, as well as calcium homeo-
stasis and neuron differentiation represented by the DN
genes (Fig. 5h; Additional file 2: Table S6). Moreover, we
compared the nodes in our TRCs with cell type specific
DEGs between no pathology and AD pathology obtained
from single cell RNA sequencing of prefrontal cortex
samples from 24 control individuals with no or little
pathology (no-pathology) and 24 age-matched individ-
uals with a spectrum of mild to severe β-amyloid and
other pathologies (AD-pathology) [49]. The comparison
revealed that Spi1 and Tnfrsf1 in the microglial TRC
were shared with microglia specific DEGs identified
from single cell RNA sequencing and Gadd45 in the
OPC TRC was with OPC specific DEGs. Taken together,
these data suggest that TRCs represent core regulatory
programs underlying early and late alterations of cellular
processes associated with prion disease.
Discussion
Perturbation of biological networks leads to activation of
a series of pathophysiological processes at early and late
stages during the course of disease progression. Tran-
scriptional regulation is a primary control mechanism
underlying temporal activation of the pathophysiological
processes. Prion diseases induce early and late expres-
sion changes of hundreds of genes, leading to alteration
of cellular processes associated with PrPSc accumulation,
microglial/astrocytic activation, synaptic degeneration,
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and neuronal cell death. Thus, decoding TRNs that de-
scribe transcriptional regulation associated with early
and late activation of cellular processes during disease
progression is essential to understanding the pathogen-
esis of prion diseases. However, the dynamics of TRNs
in prion diseases had not yet been systematically ex-
plored. In this study, we present a TRN that contains
two over-represented feed-forward loops (regulatory
Motifs 7 and 10), which can serve as the basis for tran-
scriptional regulation of target genes. Therefore, our
TRN provides transcriptional regulatory programs repre-
senting early and late alteration of target gene expression
and their associated processes during the progression of
prion diseases.
Due to the incomplete nature of the TF-target interac-
tome (and focusing on over-presented TF-pairs), our
TRN provides only a partial view of transcriptional regu-
lation in prion diseases. Some known TFs involved in
the pathogenesis of prion diseases, such as Notch con-
tributing to atrophy of dendrites in prion diseases [23],
were not included in the 18 key TFs used for the TRN.
Thus, the list of the regulatory motifs and those motifs
that are over-represented in our TRN may be incom-
plete. ChIP-chip or seq analysis of the known TFs and
the DETFs can provide further assessment of
transcriptional regulation underlying expression changes
of the genes associated with the pathophysiological fea-
tures in prion diseases. Nevertheless, the over-
represented regulatory motifs in our TRN provide an in-
formative transcriptional regulatory framework for early
and late alteration of cellular processes during disease
progression. Over-representation of Motifs 7 and 10,
consistent with those in the TRNs of yeast and E. coli
with more comprehensive TF-target interactomes, sup-
port the utility of the over-represented regulatory motifs
in our TRN.
It was previously demonstrated that the feed-forward
loops in Motifs 7 and 10 can cause delays (coherent
feed-forward loops) or accelerations (incoherent feed-
forward loops) in induction of target genes when TF
pairs are activated [2, 6]. Thus, such accelerated and de-
layed induction of target genes caused by the feed-
forward loops can be speculated to contribute to early
(EU genes) and late (LU and DN genes) alterations of
the target genes. However, the time interval in our time-
course gene expression profiling was 2 weeks for BL6-
RML and FVB-RML and 4 weeks for Prnp0/wt-RML.
Given these time intervals, considering that transcrip-
tional induction of target genes in the feed-forward
loops occurs within several hours, the effects of the
Fig. 5 Core transcriptional regulatory circuits (TRCs) in microglia and OPCs and characteristics of TRCs. A-B) TRCs in microglia (A) and OPCs (B).
Node shapes represent TFs (diamonds) and target genes (circles), and large diamonds denote DETFs. Node colors represent EU (orange), LU
(magenta), and DN (green) genes. Edge types indicate activation (arrow), inhibition, and unspecified interactions (blunted arrow). C-D)
Relationships among EU (top Venn diagram) and LU (down Venn diagram) target genes regulated by EU or LU TFs in microglial (C) and OPC (D)
TRCs. Label colors indicate EU (orange) and LU (magenta) genes. E-F) Comparison of integrated log2-fold-changes of LU target genes regulated
by EU and LU TFs in microglial (E) and OPC (F) TRCs. P-value was computed by two-tailed Student t-test. G-H) Heat map showing the numbers
of target genes included in microglial (G) and OPC (H) TRCs. Numbers of target genes involved in prion disease-associated GOBP were counted
and displayed in the heat map
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feed-forward loops on the induction kinetics of target
genes may not be apparent in our time-course gene ex-
pression data. Therefore, we considered the over-
represented motifs as the feed-forward loops that repre-
sent early and late alterations of target genes in the TRN
during disease progression.
Gene expression profiles used in this study were gen-
erated from the whole brain. Dynamic signatures of
mRNA expression observed at the whole brain level can
be different at the cellular level because of the mixing of
mRNA expression signatures across various types of
cells affected by PrPSc. Thus, the validity of dynamic ex-
pression patterns of mRNA signatures in inferring the
over-represented regulatory motifs that are operative in
individual cells are those of importance. To address this
issue, we integrated mRNA expression signatures in
seven types of cells in the brain with those in the whole
brain and further selected Motifs 7 and 10 where TF
pairs and their target genes that were expressed in the
same cell type and their expression patterns in the whole
brain were significantly correlated. The selected Motifs 7
and 10 were then considered operative in the cell types.
The integration of mRNA expression signatures at both
organellar and cellular levels might be an effective way
that can resolve the intrinsic issues of the individual
organ- and cell-level data.
Microglial and OPC TRCs shared 8 DETFs (Irf8,
Cebpa, Jun, Rela, Stat3, Spi1, Cebpb, and Srebf1) and 18
target genes (Ccl3, Cd14, Csf1, Csf1r, C3ar1, Nupr1,
Hmox1, Icam1, Itgam, Blnk, Gadd45g, Il10rb, Lyn, Tlr7,
Tgfb1, Trf, Tnfrsf1, and Dab2) that appear to be more
relevant to prion diseases than other genes in the TRCs.
Previous studies have shown potential associations of
these TFs and target genes with prion diseases or other
neurodegenerative disorders. Among the shared TFs,
Cebpa is required for differentiation of myeloid and
Cebpa expression is induced in prion diseases [2, 38]
and its expression correlates with clinical scores of in-
cipient AD [50]. A recent study shows that Cebpa ame-
liorates dendritic abnormalities induced by activation of
MT2 receptor together with miR125b in AD [51]. Irf8 is
a critical TF for microglial activation and promotes neu-
roinflammation under neurodegenerative conditions of
AD and EAE, a mouse model for multiple sclerosis [52–
54]. Spi1, also known as PU.1 in humans, is a master
regulator of microglial gene expression and reductions
in Spi1 delayed disease development of AD [55]. Spi1
and Irf8 cooperatively regulate microglial activation in
neurodegenerative conditions [53, 56], consistent with a
Motif 7 regulatory relationship including Spi1 and Irf8
in the TRCs. Phosphorylation of Jun plays key roles dur-
ing early phase of neuronal death induced by prions [45,
57]. Central nervous system-specific deletion of Rela ac-
celerates prion disease via increased neuronal cell death
[58]. Jak-Stat signaling, including Stat3, is up-regulated
in prion, Alzheimer’s, and Huntington’s diseases [43,
59], and promotes astrogliosis in scrapie-infected mice
[60]. Cebpb regulates expression of delta secretase to
modify amyloid plaque formation in AD [61] and pro-
motes glial activation in Parkinson’s disease models [62].
Srebf1 links lipogenesis to mitophagy and sporadic Par-
kinson’s disease [63], and knockdown of Srebf1 blocks
the translocation of Parkin into mitochondria, thereby
decreasing mitophagy [64].
Among the shared target genes, Cd14 is a
glycosylphosphatidylinositol-anchored receptor known
as a co-receptor for TLRs [65] and critical for Tlr2-
mediated macrophage activation [66]. Absence of Cd14
delays progression of prion diseases accompanied by in-
creased microglial activation [67]. Inhibition of Csf1r de-
creases microglial proliferation and delays neuronal
damage in prion disease [56]. Csf1r is activated together
with Cebpa and Spi1 in prion diseases, consistent with a
Motif 10 regulatory relationship including Cebpa-Spi1
and Csfr1 in the TRCs. C3ar1 inactivation attenuates
Tau pathology by reversing deregulated immune net-
works in Tauopathy models and AD [68]. Nupr1 is
emerged as an important TF in the growth and migra-
tion of human glioblastoma cells [69] and a potent regu-
lator of autolysosomal dynamics via the induction of the
SNARE proteins. Nupr1 depletion impairs autolysosomal
clearance and induces cytoplasmic vacuolization, sug-
gesting a key role in neuronal autophagy [70, 71]. Ccl3 is
a known activator of Jak-Stat signaling during prion-
induced gliosis [43, 72], and deletion of Tnfrsf1 reduces
the number of amyloid plaques and cognitive deficits in
AD mouse models [73]. Icam1 and Itgam are up-
regulated during scrapie infection [72, 74], and Icam1 is
known to be regulated cooperatively by Nfkb and Stat
signaling [75], consistent with a Motif 7 regulatory rela-
tionship including Rela-Stat3 and Icam1. Unlike the
above inflammatory genes that promotes disease pro-
gression, several inflammation-related target genes have
neuroprotective functions. Deficiency of Tgfb1 signaling
increases both Aβ accumulation and Aβ-induced neuro-
degeneration in AD models [76], and absence of Il10 ac-
celerates prion disease [77], suggesting neuroprotective
roles of Il10-Il10rb signaling. Additionally, Dab2 attenu-
ates brain injury in AD mouse models via targeting
Tgfb1 signaling [78]. Overexpression of Hmox1 contrib-
utes to mitochondrial damage in AD and Parkinson’s
disease models [79]. Iron homeostasis is regulated by
Trf, which increases with PrPSc levels, accounting for
prion-disease associated iron deficiency in scrapie-
infected mouse and hamster brains [80]. Taken together,
these and other functional associations of the shared
TFs and their target genes with neurodegenerative dis-
eases support the validity of our TRCs.
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A panel of Motifs 7 and 10 that could be operative in
a cell type act together for coordinated regulation of the
expression of target genes in the corresponding cell. To
understand the collective action of Motifs 7 and 10, we
reconstructed TRCs for microglia and OPCs. However,
the target genes in the TRCs were regulated by multiple
TFs in complicated ways, making it difficult to clearly in-
terpret transcriptional regulatory relationships between
TFs and target genes. Nevertheless, the most apparent
observation of the TRCs in operation was that both EU
and LU DETFs could regulate EU or LU target genes,
modulating the expression of EU or LU target genes at
the late stage during the course of disease progression.
Detailed functional studies can be designed to investi-
gate regulatory roles of EU or LU DETFs in regulation
of EU and LU target genes and how such regulations
contribute to PrPSc replication and accumulation, synap-
tic degeneration, and neuronal cell death.
The disease-perturbed networks become more com-
plex as disease progresses. This is why earliest possible
diagnosis (biomarkers) and therapy (drug targets) are es-
sential for treating diseases. In this study, we decoded
the dynamic transition of the TRN describing the major
pathophysiological features of prion disease and then
identified the core transcriptional regulatory circuits in
prion disease through regulatory motifs and cell type
analysis. Importantly, the core circuit demonstrates the
transcriptional regulatory pathways important for micro-
glial activation, an important early pathophysiological
feature in prion disease. The EU-DETFs (Irf8, Cebpa,
Cebpd, Nupr1) in the early regulatory pathways can
serve as biomarkers and therapeutic targets for early
diagnosis and therapy, respectively. As a result, our sys-
tems approach to decipher the dynamics of TRN
coupled with motif and cell type analyses provides spe-
cific molecular targets for early diagnosis and therapy.
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